Imciromab (CAS 126132-83-0, C111H149N27O28S2), is a white solid, widely used in medical imaging, with high affinity for tumor-associated antigens, playing a crucial role in the diagnosis and staging of certain types of cancer. Imciromab is a monoclonal antibody that specifically targets and binds to the CA19-9 antigen, which is overexpressed in various types of cancer cells. This allows for the visualization and detection of tumors through imaging techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). Imciromab has been extensively studied and proven to be effective in the diagnosis and monitoring of pancreatic, colorectal, and ovarian cancers. Its high specificity and sensitivity make it a valuable tool in the field of oncology.